WRHA Clinical Practice Guideline: Sedation for Palliative Purposes (SPP)

Similar documents
I Wanna Be Sedated: Palliative Sedation March 30, 2017 Emily L. Riegel, MD

Sedation and Delirium Questions

Sedation Hold/Interruption and Weaning Protocol ( Wake-up and Breathe )

Spontaneous Breathing Trial and Mechanical Ventilation Weaning Process

To sleep or not to sleep? PALLIATIVE SEDATION FOR REFRACTORY SYMPTOMS

Table 1: 1. : Summary y of the selection criteria.

ADMINISTRATION OF PALLIATIVE SEDATION TO THE DYING PATIENT

NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOL USE OF PROPOFOL (DIPRIVAN) FOR VENTILATOR MANAGEMENT

end of life best practice guidelines HPC hpcconnection.ca interdisciplinary dignity collaborative suffering Palliative Sedation Therapy sedation

Is it palliative sedation or just good symptom management?

Midazolam for Agitation - Baseline

Barb Supanich, RSM, MD, FAAHPM Medical Director, Palliative Care Team September 9, 2010

Sedation Guidelines for Air Ambulance Transfer of Psychiatric Patients

Physician Assisted Death (PAD) - Practical and Ethical Implications in the Hospice Setting and in the Home

The Waterloo Wellington Palliative Sedation Protocol

The Quebec Palliative Sedation Guidelines. Rose DeAngelis, N, MSc(A), CHPCN (C)

Hospice Palliative Care Association of South Africa

Guideline for Estimating Length of Survival in Palliative Patients

Agitation. Susan Emmens Palliative Care Clinical Nurse Specialist

HPNA Position Statement Palliative Sedation at End of Life

PHYSICIAN'S ORDERS Mark in for desired orders. If is blank, order is inactive. VENTILATOR SEDATION / ANALGESIC / DELIRIUM ORDER

Collaborative Regional Benchmarking Group (North of England, North Yorkshire & Humber and West Yorkshire)

4/10/2018. Preparing for Death. Describe a Recent Death You Have Observed. The Nurse, Dying and Death

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Symptom Management Pocket Guides: DELIRIUM

Withdrawal of Care in the ICU

UCSF PAIN SUMMIT /8/15

Sedation in Palliative Care. Dr Katie Frew Consultant in Palliative Medicine Northumbria Healthcare NHS FT

Dementia and End of Life Care

Palliative Sedation. B. Craig Weldon, MD. That sweet, deep sleep, so close to tranquil death. The Aeneid, Virgil [70-19 B.C.E]

Palliative Performance Scale (PPS)

Controlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020

Approach to symptom control near the end-of-life

Pasero Opioid induced Sedation Scale (POSS) and Sedation Precautions for Net Access. Clinical Informatics March 2016

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

Sedation and Analgesia in the Critically Ill

Sit Down, Lean In. The Importance Of Connection In Exploring Suffering. Community Cancer Care 2016 Educational Conference Sept.

Palliative Medicine in Critical Care Not Just Hospice. Robin. Truth or Myth 6/11/2015. Francine Arneson, MD Palliative Medicine

Sedation and delirium- drugs and clinical management

Restlessness Emotional support Self care

describe the epidemiological and clinical features along the illness trajectories of specific lifelimiting

patient group direction

Dyspnea: The top things you need to you know! Dr. Megan Sellick & Dr. Lawrence Lee Edmonton Zone Palliative Care Program

Care in the Last Days of Life

Criteria and Guidance for Referral to Specialist Palliative Care Services

Symptom Management In Comfort End-Of-Life Care Of Pneumonia

Essential Palliative Care Skills For Every Clinician

The Role of Palliative Care in Advanced Lung Disease

Specialist Palliative Care Referral for Patients

Road Blocks in Non-Cancer Palliative Care Obstacles observed from outpatient non-cancer palliative practice.

To prevent and relieve suffering, and promote quality of life at every stage of life

Assessment of physical monitoring following rapid tranquillisation. Stephen Dye

Original Article. Published by Elsevier. All rights reserved. Key Words Sedation, definition, palliative care, multidimensional scaling

Promoting Quality at End of Life for those Living with Dementia

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS

Primary Palliative Care Skills

Community and Mental Health Services. Palliative Care. Criteria and

Hospice Services. Prior Authorization Required: Additional Information:

SPAGG. Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation

NeuroPI Case Study: Palliative Care Counseling and Advance Care Planning

Management of Severe Agitation

THE ROLE OF PALLIATIVE CARE IN TREATMENT OF PATIENTS WITH CHRONIC, INFECTIOUS DISEASE

Supplementary appendix

Opioid-induced Sedation

Palliative Care and End of Life Care

Foundations of Palliative Care Series

Responding to Requests for Hastened Death in an Environment Where the Practice is Legally Prohibited

Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals

2514 Stenson Dr Cedar Park TX Fax

PART one. The Palliative Care Spectrum: Providing Care Across Settings

CLINICAL GUIDELINES FOR END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES

Ventilator-Associated Event Prevention: Innovations

Pediatric Palliative Care

2/12/2016. Disclosure. Objectives. The Hospice Medical Director: What Should They Be Doing?

Rule Governing the Prescribing of Opioids for Pain

North Wales Critical Care Network

I have no financial disclosures.

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

SEDATIVE-HYPNOTICS. Mr. D.Raju, M.pharm, Lecturer

New Zealand Palliative Care: A Working Definition.

Hospice and Palliative Medicine

Pain Module. Opioid-RelatedRespiratory Depression (ORRD)

Critical Care Strategic Clinical Network Provincial ICU Delirium Framework

Specialist Palliative Care Service Referral Criteria and Guidance

Dr. Andrea Johnson Saskatoon Health Region/Saskatoon Cancer Centre September 30, 2016

Management of Dyspnea and Cough in Lung Cancer

Palliative Sedation in Patients with Advanced Cancer Followed at Home: A Systematic Review

KICU Spontaneous Awakening Trial (SAT) Questionnaire

European PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam

Ventilator-Associated Pneumonia Prevention Bundle 2010 Revised Edition (JSICM-VAP Bundle)

Palliative Medicine Overview. Francine Arneson, MD Palliative Medicine

Symptoms Assess symptoms and needs across all domains. Screen using Edmonton Symptom Assessment System (ESAS) for: Pain Nausea Depression

The evolving role of palliative Sedation in the era of Medical Assistance in Dying (MAID)

Timothy W. Kirk, PhD Ethics Consultant VNSNY Hospice and Palliative Care. Judith K. Schwarz, RN, MSN, PhD Consultant, End of Life Decision Making

Delirium. Assessment and Management

Palliative sedation in an international perspective

Patient Outcomes in Palliative Care for South Australia

Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)

Guidelines for the management of agitation in the last weeks of life

Transcription:

WRHA Clinical Practice Guideline: Sedation for Palliative Purposes (SPP) Developed by: WRHA Regional Working Group Mike Harlos MD, CCFP(PC), FCFP Professor and Section Head, Palliative Medicine, University of Manitoba Medical Director, WRHA Adult and Pediatric Palliative Care and Janice Nesbitt RN MN, CNS WRHA Palliative Care Program

No conflicts of interest to disclose

Objectives Background and purpose of guideline Definition Criteria/ Indications for SPP Decision- making Medications used in SPP Ongoing monitoring and documentation Other Resources

Background Symptom control in the dying patient has advanced considerably in the past decades but there are instances, despite the efforts of all involved, when symptoms remain uncontrolled and intolerable to the patient. Sedation for Palliative Purposes* (SPP) is a valuable therapeutic intervention that, in certain cases, can and should be initiated to facilitate a more comfortable death. Intentionally referred to as sedation for palliative purposes as this term is a more specific description of the goal of the proposed intervention.

CPG Purpose To provide recommendations in the practice of sedation for palliative purposes (SPP) regarding: Indications Decision-making process Medications Monitoring Documentation To provide clinical support for the following care settings: Adult clinical practice Pediatric clinical practice Designated palliative care units Hospice Community and tertiary health care facilities Long term care facilities Home

Reasons for Sedation Symptoms Stone et al. (1997) (n=115) Morita et al. (1999) (n= 157) Porta Sales (2001) Bobb (2016) Delirium 60% 42% 39% 54% Dyspnea 20% 41% 38% 30% Pain 20% 13% 22% 17% Bleeding - - 9% - N/V - 2% 6% 5% Fatigue - - 20% - Psych 26% 2% 21% 19%

Palliative Sedation vs. Euthanasia (MAID) Palliative Sedation Euthanasia Goal Decrease suffering Decrease suffering Intent To sedate To end the life of the patient Process Immediate Outcome Administration of sedating drug doses, titrated to effect Decreased level of consciousness Administration of a lethal drug dose Death Cause of Death Natural progression of underlying illness Medications administered

Definition Sedation for Palliative Purposes is the planned and proportionate use of sedation to reduce consciousness in an imminently dying patient, with the goal to relieve suffering that is intolerable to the patient and refractory to interventions acceptable to the patient.

Palliative Sedation (Sedation for Palliative Purposes) Sedation for Palliative Purposes is the planned and proportionate use of sedation to reduce consciousness in an imminently dying patient, with the goal to relieve suffering that is intolerable to the patient and refractory to interventions acceptable to the patient. The intention of the intervention is to sedate, rather than sedation being the undesired yet predictable side effect of medications such as opioids or anti-nauseants.

Palliative Sedation (Sedation for Palliative Purposes) Sedation for Palliative Purposes is the planned and proportionate use of sedation to reduce consciousness in an imminently dying patient, with the goal to relieve suffering that is intolerable to the patient and refractory to interventions acceptable to the patient Medications are titrated to the lowest effective dose. Respiratory rate and pattern are watched to prevent medication-related resp. depression

Palliative Sedation (Sedation for Palliative Purposes) Sedation for Palliative Purposes is the planned and proportionate use of sedation to reduce consciousness in an imminently dying patient, with the goal to relieve suffering that is intolerable to the patient and refractory to interventions acceptable to the patient. Expected natural death within 1-2 weeks from the underlying lifelimiting condition, to avoid hastening the death through dehydration caused by prolonged sedation.

Palliative Sedation (Sedation for Palliative Purposes) Sedation for Palliative Purposes is the planned and proportionate use of sedation to reduce consciousness in an imminently dying patient, with the goal to relieve suffering that is intolerable to the patient and refractory to interventions acceptable to the patient The person experiencing the suffering is in the best position to judge intolerable

Palliative Sedation (Sedation for Palliative Purposes) Sedation for Palliative Purposes is the planned and proportionate use of sedation to reduce consciousness in an imminently dying patient, with the goal to relieve suffering that is intolerable to the patient and refractory to interventions acceptable to the patient. Proposed interventions may seem minor or trivial to the health care team, but unduly burdensome to the patient.

Criteria estimated prognosis less than 2 wks intolerable suffering refractory to accepted interventions goals of care should be consistent with WRHA ACP 'C' health care team should have the needed expertise to undertake SPP in a manner consistent with the approach described in this document, including assessment, medication selection and use, monitoring, and family and staff support if the healthcare team involved lacks expertise in SPP, they must consult the WRHA Palliative Care program

Why 2 weeks? SPP causes abrupt cessation of fluid intake impact is similar to massive CVA or feeding tube withdrawal, where survival is generally 1-2 wks in the best judgment of the involved clinicians if the natural course of the underlying illness is expected to result in death within 1-2 wks, palliative sedation is not likely to cause the patient s death an expected natural death within 1-2 weeks from an underlying life-limiting condition is a common criterion in palliative sedation guidelines (Schildmann & Schildmann, 2014).

What SPP is not Temporary sedation of a patient to manage symptoms Respite sedation An unintended adverse effect of treatment (e.g.. opioidrelated sedation) Sedation with the temporary use of antipsychotics to treat delirium Procedure-related sedation Sedation intended to hasten or cause death The sedation of patients whose life expectancy is more than 2 weeks.

Decision Making should involve: the patient/sdm; family; healthcare team. Documentation is key and should include: intolerable and refractory nature of the suffering; prognosis; goals of care; target level of sedation (i.e. RASS- PAL- Appendix B and C); and Details of the discussions with the patient, SDM and/or family and the healthcare team Should be re-evaluated on an ongoing basis (not a one way intervention)

Other Components of Care Hydration and Nutrition Often an area of concern should be addressed preemptively with all involved including health care team Should consider each as distinct issues In general, medically administered hydration/nutrition is not consistent with an approach that allows an expected death to unfold naturally, and does not address comfort issues Review of Concurrent Medications Review and streamline medications This includes the use of supplemental oxygen

Medications used for SPP Little evidence guiding medication choices Some common themes in published approaches Care setting impacts options Opioids Not primary sedatives, rather are analgesics with sedating side effects Not sole agent Pre-existing opioid needs will continue Benzodiazepines Rarely sole agent Paradoxical effect possible Antipsychotics generally select those with higher sedating characteristics, e.g. methotrimeprazine

Ongoing assessment Monitoring Baseline assessment of full clinical presentation and plan Prior to subsequent doses If a changes in clinical presentation or plan of care Minimum of q4h Documentation Appearance of comfort Depth of sedation Respiratory rate and pattern A tool to measure the patient s level of sedation should be used. The Richmond Agitation Sedation Scale- Palliative (RASS- PAL)

Why Document Respiratory Rate And Pattern? the manner of dying from acute sedative overdose is typically through respiratory depression, either with apnea or (more commonly) progressive slowing of regular respiratory rate in contrast, the typical end-of-life respiratory pattern in progressive illness includes fast shallow breathing, progressing to apneic episodes interspersed with clusters of rapid breaths it is possible that individual circumstances of SPP will be scrutinized: staff feeling complicit in covert euthanasia family members may express concern that SPP caused death death may be reviewed by the Medical Examiner's Office in compliance with the Fatality Enquiries Act (e.g. Long Term Care setting, reportable underlying condition), and comprehensive documentation is important in supporting such reviews

in the absence of documentation of respiratory rate and pattern, there is limited information to indicate that the sedating medications did not cause or contribute to the patient s death support for the health care team s practice is even further challenged when there is no documentation for the indications and effects of prn doses

Richmond Agitation- Sedation Scale: Palliative Version (RASS-PAL) +4 Combative Overtly combative, violent, immediate danger to staff (e.g. throwing items); +/- attempting to get out of bed or chair +3 Very agitated Pulls or removes lines (e.g. IV/SQ/Oxygen tubing) or catheter(s); aggressive, +/- attempting to get out of bed or chair +2 Agitated Frequent non-purposeful movement, +/- attempting to get out of bed or chair +1 Restless Occasional non-purposeful movement, but movements not aggressive or vigorous 0 Alert and calm -1 Drowsy Not fully alert, but has sustained awakening (eye-opening/eye contact) to voice (10 seconds or longer) -2 Light sedation -3 Moderate sedation -4 Deep sedation -5 Not rousable Briefly awakens with eye contact to voice (less than 10 seconds) Any movement (eye or body) or eye opening to voice (but no eye contact) No response to voice, but any movement (eye or body) or eye opening to stimulation by light touch No response to voice or stimulation by light touch Adapted with permission from Bush, S.H. et al. (2014). The Richmond Agitation- Sedation Scale modified for palliative care inpatients (RASS-PAL): a pilot study exploring validity and feasibility in clinical practice. BMC Palliative Care, 13, 17-25.

Other Resources Available If there are differences in opinion between the patient/sdm/ family and/or members of the healthcare team, consider the following additional resources for assistance: Second opinions; Available pain or symptom management specialists; Ethics committees and/ or services; WRHA Ethics Decision Making Framework (http://www.wrha.mb.ca/about/ethics/framework.php) Available psychosocial support advisors Available religious or spiritual care advisors; Available cultural advisors; Social work Patient advocates; and/or Other facility or regional resources for support.

Other Resources Available The WRHA Palliative Care Service is available 24/7 to provide support when: The healthcare team does not possess expertise/ experience in assessing the need for or administering SPP SPP is being considered in a care settings which may have limited exposure to this intervention Consensus cannot be reached regarding the use of SPP Uncertainty exists about the patient's decision-making capacity There are questions or concerns regarding prognostication in the context of assessing an individual for SPP

Questions